Group of people collaborating around a table.

See our key takeaways from this FDA workshop designed to solicit input on increasing the enrollment of historically underrepresented populations and encouraging clinical study participation reflecting the prevalence of the disease or condition among demographic subgroups.

Top 5 Insights from FDA Public Workshop to Enhance Clinical Trial Diversity
By Lya Rebelo, Manager, Product Success

The two-day workshop1 fulfills the requirement under Section 3603 of the Food and Drug Omnibus Reform Act of 2022 (FDORA)

  1. Expanded definition of diversity

    The FDA emphasizes a broader definition of diversity beyond race, ethnicity, and gender, including groups like pregnant and lactating persons, children and the elderly, and individuals with intellectual, developmental, or mental health conditions, indicating a shift towards inclusivity in clinical trials.

  2. Early planning is crucial: from protocol design to patient engagement

    Panelists highlighted the importance of broadening eligibility criteria during trial design and engaging with communities early in the clinical trial process, even as early as Phase I, which will be crucial to avoid delays in recruiting underrepresented patient populations.

  3. Data challenges and use of RWD

    Data collection, integrity, and standardization are significant challenges, especially with varying global standards and legal limitations on collecting sensitive data such as race and ethnicity. Further challenges in collecting data on non-traditional attributes such as gender identity, lactation status, and disability were hot topics on day 1.

    Sponsors should carefully assess the adequacy of the use of RWD, ensuring the RWD source is fit for purpose.

  4. Expectation vs. reality: early findings

    Analysis of diversity plans (Project Equity2) revealed that although 87% of plans submitted during the initial one-year period contained all five recommended components, only a small proportion of plans on which the agency provided feedback were deemed acceptable (6%).

  5. It takes a village and new roles to enhance diversity in clinical trials

    The FDA acknowledges that a combined effort from all parties involved in clinical trials is essential to ensure success.

    “FDA is only one piece of the puzzle. It takes the combined effort of all interested parties in the clinical trials enterprise,”  Patricia Cavazzoni, Director, FDA Center of Drug Evaluation and Research, highlighted in her opening remarks.

    Boehringer Ingelheim is creating cross-functional new roles titled Clinical Trial Diversity Lead and Team of Diversity Strategists to support its diversity plans.


What are sponsors and CROs expecting?

The FDA focused less on legal and regulatory comments at the recent workshop. However, FDORA mandates the FDA to update existing guidance or issue new guidance according to the requirements in FDORA no later than 12 months from when FDORA was signed into law3 on Dec. 29, 2022.

Sponsors and CROs anxiously await the new/updated guidance to be published soon.


Did you attend the FDA workshop?

Comments are due until Jan. 30, 2024, you can submit your comments here

Want to learn more? With the Sitetrove Diversity Module robust site and investigator intelligence from Sitetrove and rich, real-world US demographic data support diverse patient recruitment.


References:

1 FDA Final Agenda Public Workshop Nov. 29–30, 2023

2 Project Equity – Diversity Plans – Oncology – Year 1 Experience

3 Public Law No. 117-328, Chapter 1, Clinical Trial Diversity and Modernization

Related resources

Multicultural group of people representing the importance of diversity in trials and recruitment.
NOV 29, 2023
ユースケース
研究開発支援サービス

Make the Recruitment and Enrollment of Diverse Populations a Priority — and a Success

A sponsor planning a Phase II trial needs to support goals and objectives outlined in its FDA Race & Ethnicity Diversity Plan. See Sitetrove in action.

A digital representation of the future of healthcare, showcasing the integration of technology and medicine.
JUN 01, 2023
ホワイトペーパー
研究開発支援サービス

The Need for Better Diversity Data in Clinical Trial Benchmarking and Feasibility

Just as marginalized patients face barriers to clinical trial participation, study sponsors face challenges in obtaining clinical trial diversity data.

A diverse group of people looking up.
NOV 15, 2023
ニュース記事
研究開発支援サービス

3 Ways Clinical Trial Diversity Can Put Sponsors On Top

Since the FDA’s draft guidance in 2022, the industry has redoubled its efforts to incorporate diversity at pivotal points in the clinical trial process.